Table of Contents
Table of Contents 2
List of Tables 9
List of Figures 14
Introduction 15
Global Markets Direct Report Coverage 15
Multiple Sclerosis Overview 16
Therapeutics Development 17
An Overview of Pipeline Products for Multiple Sclerosis 17
Multiple Sclerosis Therapeutics under Development by Companies 19
Multiple Sclerosis Therapeutics under Investigation by Universities/Institutes 26
Late Stage Products 30
Comparative Analysis 30
Mid Clinical Stage Products 31
Comparative Analysis 31
Early Clinical Stage Products 32
Comparative Analysis 32
Discovery and Pre-Clinical Stage Products 33
Comparative Analysis 33
Multiple Sclerosis Therapeutics - Products under Development by Companies 34
Multiple Sclerosis Therapeutics - Products under Investigation by Universities/Institutes 45
Companies Involved in Multiple Sclerosis Therapeutics Development 49
Genzyme Corporation 49
Baxter International Inc. 49
Johnson & Johnson 50
F. Hoffmann-La Roche Ltd. 50
Biogen Idec Inc. 51
Sanofi-Aventis 51
Eli Lilly and Company 52
GlaxoSmithKline plc 52
Daiichi Sankyo Company, Ltd 53
Micromet, Inc. 53
Cytokine PharmaSciences, Inc. 54
Takeda Pharmaceutical Company Limited 54
XenoPort, Inc. 55
BioLineRx, Ltd. 55
Reliance Life Sciences Pvt. Ltd. 56
Apitope International NV 56
Nycomed International Management GmbH 57
Teijin Pharma Limited 57
Novartis AG 58
Ichor Medical Systems, Inc. 58
Acorda Therapeutics, Inc. 59
Actelion Ltd 59
Astellas Pharma Inc. 60
Dong-A Pharmaceutical Co., Ltd. 60
Eisai Co., Ltd. 61
Elan Corporation, plc 61
Glenmark Pharmaceuticals Ltd. 62
Hanmi Pharmaceutical Co Ltd 62
MDRNA, Inc. 63
Ono Pharmaceutical Co., Ltd. 63
Rigel Pharmaceuticals, Inc. 64
Teva Pharmaceutical Industries Limited 64
Genmab A/S 65
AutoImmune Inc. 65
Paratek Pharmaceuticals, Inc. 66
Celgene Corporation 66
Vernalis plc 67
SRI International 67
Merck KGaA 68
4SC AG 68
Addex Pharmaceuticals 69
Evotec Aktiengesellschaft 69
Genesis Research and Development Corporation Ltd. 70
Hemispherx Biopharma, Inc. 70
Hollis-Eden Pharmaceuticals, Inc. 71
IntelGenx Technologies Corp. 71
Antisense Therapeutics Limited 72
AVANIR Pharmaceuticals 72
Karo Bio 73
Almirall, S.A. 73
Lpath, Inc. 74
MediciNova, Inc. 74
Medivir AB 75
BioMS Medical Corp. 75
Bionomics Limited 76
PROLOR Biotech, Inc. 76
MultiCell Technologies, Inc. 77
Nutra Pharma Corporation 77
Opexa Therapeutics, Inc. 78
Compugen Ltd. 78
Critical Outcome Technologies Inc. 79
Accentia Biopharmaceuticals, Inc. 79
BTG International Ltd 80
Flamel Technologies S.A. 80
RegeneRx Biopharmaceuticals, Inc. 81
ProMetic Life Sciences Inc. 81
Cytos Biotechnology AG 82
Pluristem Therapeutics Inc. 82
Galapagos NV 83
Synta Pharmaceuticals Corp. 83
Sareum Holdings plc 84
Santhera Pharmaceuticals Holding AG 84
Shenzhen Beike Biotechnology Co., Ltd. 85
Stem Cell Therapeutics Corp. 85
InDex Pharmaceuticals AB 86
Digna Biotech, S.L. 86
Bayhill Therapeutics, Inc. 87
Probiodrug AG 87
BioMAS Ltd. 87
Trophos SA 88
MAT Biopharma 88
Artielle ImmunoTherapeutics, Inc. 89
Affectis Pharmaceuticals AG 89
ProtAffin Biotechnologie AG 89
Circassia Holdings Ltd. 90
Allozyne, Inc. 90
Clinquest Group, B.V. 91
Cognition Pharmaceuticals LLC 91
Q Therapeutics, Inc. 91
Vaccinex, Inc. 92
Pantarhei Bioscience BV 92
Peptimmune, Inc. 93
Innate Therapeutics Limited 93
Kineta, Inc. 93
Reata Pharmaceuticals, Inc. 94
Xention Limited 94
Txcell SA 95
Theraclone Sciences, Inc. 95
Virobay Inc. 95
Genexine Co., Ltd. 96
Bolder Biotechnology, Inc. 96
Aegis Therapeutics, LLC 97
Xencor, Inc. 97
Adeona Pharmaceuticals, Inc. 97
Trillium Therapeutics Inc. 98
ChemoCentryx, Inc. 98
Biovista Inc. 99
CBio Limited 99
SanBio, Inc. 100
AB Science 100
Provid Pharmaceuticals, Inc. 100
Epiphany Biosciences, Inc. 101
OncoImmune, Inc. 101
Hy BioPharma Inc. 102
PharmaEssentia Corporation 102
KAHR medical Ltd. 102
M's Science Corporation 103
Pharnext SAS 103
Cellceutix Pharmaceuticals, Inc. 104
British Canadian Biosciences Corp. 104
Vakzine Projekt Management GmbH 104
Receptos, Inc. 105
Biopartners Holdings AG 105
Xechem International, Inc 106
Cellmid Ltd 106
Cognosci, Inc. 107
Immune Technologies and Medicine 107
Multiple Sclerosis - Therapeutics Assessment 108
Assessment by Monotherapy Products 108
Assessment by Combination Products 109
Assessment by Route of Administration 110
Assessment by Molecule Type 113
Late Stage Drug Profiles 116
Teriflunomide - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Laquinimod - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
RG1594 - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Campath - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
BIIB017 - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
RPI-78M - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
Myloral - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
Trimesta - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
AB1010 - Drug Profile 144
Product Description 144
Mechanism of Action 144
R&D Progress 144
Rebif - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
Riluzole - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
Aspirin - Drug Profile 157
Product Description 157
Mechanism of Action 157
R&D Progress 157
Fampyra - Drug Profile 164
Product Description 164
Mechanism of Action 164
R&D Progress 164
Ampydin - Drug Profile 167
Product Description 167
Mechanism of Action 167
R&D Progress 167
Venilon - Drug Profile 169
Product Description 169
Mechanism of Action 169
R&D Progress 169
Multiple Sclerosis Therapeutics – Drug Profile Updates 170
Multiple Sclerosis Therapeutics - Discontinued Products 180
Multiple Sclerosis - Featured News 181
Oct 11, 2011: Phase II Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions In Patients Receiving Interferon Beta Therapy 181
Sep 19, 2011: Adeona Completes Planned Enrollment In Phase II Multiple Sclerosis Clinical Trial 181
Sep 06, 2011: AB Science Recruits First Patient In Phase III Study Of Masitinib In Progressive Multiple Sclerosis 183
Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection 183
Aug 09, 2011: Biogen Idec And Abbott Announce Positive Top-Line Results From Phase II Trial Of Daclizumab HYP In Relapsing-Remitting Multiple Sclerosis 184
Aug 08, 2011: Allergan’s BOTOX Receives Positive Opinion In 14 European Countries For Urinary Incontinence In Patients With Multiple Sclerosis Or Spinal Cord Injury 185
Aug 02, 2011: Actelion's Selective S1P1 Receptor Agonist Ponesimod Successful In Mid-stage Trial For Multiple Sclerosis 186
Aug 01, 2011: Teva And Active Biotech Announce Results Of Phase III BRAVO Trial Reinforce Unique Profile Of Laquinimod For Multiple Sclerosis Treatment 188
Jul 20, 2011: Daval International Announces Completion Of Phase II Trial For Treatment Of Bladder Dysfunction With AIMSPRO In Secondary Progressive Multiple Sclerosis 189
Jul 19, 2011: Advancell And Neurotec Pharma Announce Initiation Of Phase IIa Study Of NT-KO-003 For Multiple Sclerosis 189
Appendix 191
Methodology 191
Coverage 191
Secondary Research 191
Primary Research 191
Expert Panel Validation 192
Contact Us 192
Disclaimer 192
List of Tables
Number of Products Under Development for Multiple Sclerosis, H2 2011 17
Products under Development for Multiple Sclerosis – Comparative Analysis, H2 2011 18
Number of Products under Development by Companies, H2 2011 20
Number of Products under Development by Companies, H2 2011 21
Number of Products under Development by Companies, H2 2011 22
Number of Products under Development by Companies, H2 2011 23
Number of Products under Development by Companies, H2 2011 24
Number of Products under Development by Companies, H2 2011 25
Number of Products under Investigation by Universities/Institutes, H2 2011 27
Number of Products under Investigation by Universities/Institutes, H2 2011 28
Number of Products under Investigation by Universities/Institutes, H2 2011 29
Comparative Analysis by Late Stage Development, H2 2011 30
Comparative Analysis by Mid Clinical Stage Development, H2 2011 31
Comparative Analysis by Early Clinical Stage Development, H2 2011 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011 33
Products under Development by Companies, H2 2011 34
Products under Development by Companies, H2 2011 35
Products under Development by Companies, H2 2011 36
Products under Development by Companies, H2 2011 37
Products under Development by Companies, H2 2011 38
Products under Development by Companies, H2 2011 39
Products under Development by Companies, H2 2011 40
Products under Development by Companies, H2 2011 41
Products under Development by Companies, H2 2011 42
Products under Development by Companies, H2 2011 43
Products under Development by Companies, H2 2011 44
Products under Investigation by Universities/Institutes, H2 2011 45
Products under Investigation by Universities/Institutes, H2 2011 46
Products under Investigation by Universities/Institutes, H2 2011 47
Products under Investigation by Universities/Institutes, H2 2011 48
Genzyme Corporation, H2 2011 49
Baxter International Inc., H2 2011 49
Johnson & Johnson, H2 2011 50
F. Hoffmann-La Roche Ltd., H2 2011 50
Biogen Idec Inc., H2 2011 51
Sanofi-Aventis, H2 2011 51
Eli Lilly and Company, H2 2011 52
GlaxoSmithKline plc, H2 2011 52
Daiichi Sankyo Company, Ltd, H2 2011 53
Micromet, Inc., H2 2011 53
Cytokine PharmaSciences, Inc., H2 2011 54
Takeda Pharmaceutical Company Limited, H2 2011 54
XenoPort, Inc., H2 2011 55
BioLineRx, Ltd., H2 2011 55
Reliance Life Sciences Pvt. Ltd., H2 2011 56
Apitope International NV, H2 2011 56
Nycomed International Management GmbH, H2 2011 57
Teijin Pharma Limited, H2 2011 57
Novartis AG, H2 2011 58
Ichor Medical Systems, Inc., H2 2011 58
Acorda Therapeutics, Inc., H2 2011 59
Actelion Ltd, H2 2011 59
Astellas Pharma Inc., H2 2011 60
Dong-A Pharmaceutical Co., Ltd., H2 2011 60
Eisai Co., Ltd., H2 2011 61
Elan Corporation, plc, H2 2011 61
Glenmark Pharmaceuticals Ltd., H2 2011 62
Hanmi Pharmaceutical Co Ltd, H2 2011 62
MDRNA, Inc., H2 2011 63
Ono Pharmaceutical Co., Ltd., H2 2011 63
Rigel Pharmaceuticals, Inc., H2 2011 64
Teva Pharmaceutical Industries Limited, H2 2011 64
Genmab A/S, H2 2011 65
AutoImmune Inc., H2 2011 65
Paratek Pharmaceuticals, Inc., H2 2011 66
Celgene Corporation, H2 2011 66
Vernalis plc, H2 2011 67
SRI International, H2 2011 67
Merck KGaA, H2 2011 68
4SC AG, H2 2011 68
Addex Pharmaceuticals, H2 2011 69
Evotec Aktiengesellschaft, H2 2011 69
Genesis Research and Development Corporation Ltd., H2 2011 70
Hemispherx Biopharma, Inc., H2 2011 70
Hollis-Eden Pharmaceuticals, Inc., H2 2011 71
IntelGenx Technologies Corp., H2 2011 71
Antisense Therapeutics Limited, H2 2011 72
AVANIR Pharmaceuticals, H2 2011 72
Karo Bio, H2 2011 73
Almirall, S.A., H2 2011 73
Lpath, Inc., H2 2011 74
MediciNova, Inc., H2 2011 74
Medivir AB, H2 2011 75
BioMS Medical Corp., H2 2011 75
Bionomics Limited, H2 2011 76
PROLOR Biotech, Inc., H2 2011 76
MultiCell Technologies, Inc., H2 2011 77
Nutra Pharma Corporation, H2 2011 77
Opexa Therapeutics, Inc., H2 2011 78
Compugen Ltd., H2 2011 78
Critical Outcome Technologies Inc., H2 2011 79
Accentia Biopharmaceuticals, Inc., H2 2011 79
BTG International Ltd, H2 2011 80
Flamel Technologies S.A., H2 2011 80
RegeneRx Biopharmaceuticals, Inc., H2 2011 81
ProMetic Life Sciences Inc., H2 2011 81
Cytos Biotechnology AG, H2 2011 82
Pluristem Therapeutics Inc., H2 2011 82
Galapagos NV, H2 2011 83
Synta Pharmaceuticals Corp., H2 2011 83
Sareum Holdings plc, H2 2011 84
Santhera Pharmaceuticals Holding AG, H2 2011 84
Shenzhen Beike Biotechnology Co., Ltd., H2 2011 85
Stem Cell Therapeutics Corp., H2 2011 85
InDex Pharmaceuticals AB, H2 2011 86
Digna Biotech, S.L., H2 2011 86
Bayhill Therapeutics, Inc., H2 2011 87
Probiodrug AG, H2 2011 87
BioMAS Ltd., H2 2011 88
Trophos SA, H2 2011 88
MAT Biopharma, H2 2011 88
Artielle ImmunoTherapeutics, Inc., H2 2011 89
Affectis Pharmaceuticals AG, H2 2011 89
ProtAffin Biotechnologie AG, H2 2011 90
Circassia Holdings Ltd., H2 2011 90
Allozyne, Inc., H2 2011 90
Clinquest Group, B.V., H2 2011 91
Cognition Pharmaceuticals LLC, H2 2011 91
Q Therapeutics, Inc., H2 2011 92
Vaccinex, Inc., H2 2011 92
Pantarhei Bioscience BV, H2 2011 92
Peptimmune, Inc., H2 2011 93
Innate Therapeutics Limited, H2 2011 93
Kineta, Inc., H2 2011 94
Reata Pharmaceuticals, Inc., H2 2011 94
Xention Limited, H2 2011 94
Txcell SA, H2 2011 95
Theraclone Sciences, Inc., H2 2011 95
Virobay Inc., H2 2011 96
Genexine Co., Ltd., H2 2011 96
Bolder Biotechnology, Inc., H2 2011 96
Aegis Therapeutics, LLC, H2 2011 97
Xencor, Inc., H2 2011 97
Adeona Pharmaceuticals, Inc., H2 2011 98
Trillium Therapeutics Inc., H2 2011 98
ChemoCentryx, Inc., H2 2011 99
Biovista Inc., H2 2011 99
CBio Limited, H2 2011 99
SanBio, Inc., H2 2011 100
AB Science, H2 2011 100
Provid Pharmaceuticals, Inc., H2 2011 101
Epiphany Biosciences, Inc., H2 2011 101
OncoImmune, Inc., H2 2011 101
Hy BioPharma Inc., H2 2011 102
PharmaEssentia Corporation, H2 2011 102
KAHR medical Ltd., H2 2011 103
M's Science Corporation, H2 2011 103
Pharnext SAS, H2 2011 103
Cellceutix Pharmaceuticals, Inc., H2 2011 104
British Canadian Biosciences Corp., H2 2011 104
Vakzine Projekt Management GmbH, H2 2011 105
Receptos, Inc., H2 2011 105
Biopartners Holdings AG, H2 2011 105
Xechem International, Inc, H2 2011 106
Cellmid Ltd, H2 2011 106
Cognosci, Inc., H2 2011 107
Immune Technologies and Medicine, H2 2011 107
Assessment by Monotherapy Products, H2 2011 108
Assessment by Combination Products 109
Assessment by Stage and Route of Administration, H2 2011 112
Assessment by Molecule Type, H2 2011 115
Multiple Sclerosis Therapeutics – Drug Profile Updates 170
Discontinued Products 180
List of Figures
Number of Products under Development for Multiple Sclerosis, H2 2011 17
Products under Development for Multiple Sclerosis – Comparative Analysis, H2 2011 18
Products under Development by Companies, H2 2011 19
Products under Investigation by Universities/Institutes, H2 2011 26
Late Stage Products, H2 2011 30
Mid Clinical Stage Products, H2 2011 31
Early Clinical Stage Products, H2 2011 32
Discovery and Pre-Clinical Stage Products, H2 2011 33
Assessment by Monotherapy Products, H2 2011 108
Assessment by Combination Products, H2 2011 109
Assessment by Route of Administration, H2 2011 110
Assessment by Stage and Route of Administration, H2 2011 111
Assessment by Molecule Type, H2 2011 113
Assessment by Stage and Molecule Type, H2 2011 114
